Nav: Home

New 'organ-on-a-chip' system holds promise for drug toxicity screening

March 02, 2020

Researchers in the US have developed a new multi-organ-on-a-chip to test how new drugs affect the human body's vital organs.

Developing new drugs can come at enormous financial cost, which can be wasted if the drug must be withdrawn due to unforeseen side effects.

The research team believes their new system - containing representations of liver, heart, vasculature, lungs, testis, and either colon or brain tissues - could help avoid such cases.

In their study, published in the journal Biofabrication, they demonstrated its effectiveness by using it to screen a selection of drugs that were recalled from the market by the US Federal Drug Administration (FDA).

Professor Anthony Atala, from the Wake Forest Institute for Regenerative Medicine (WFIRM), Winston-Salem, US, is the study's senior author. He said: "The development of new drugs can take a decade and a half, from preclinical studies to reaching the market. Around one in 5,000 drug candidates successfully completes this journey. Additionally, the cost for bringing a single drug to market, with all direct and indirect expenses accounted for, can climb as high as $2.6 billion.

"Unfortunately, the human and financial costs can be even more dramatic if a drug is later found to be harmful and must be withdrawn. For example, Merck & Co. paid $4.85 billion to settle 27,000 cases and another $830 million dollars to settle shareholder lawsuits after one of its drugs caused adverse effects. The human costs of adverse drug reactions, meanwhile, manifest themselves as a leading cause of hospitalization in the United States, with up to 5.3 per cent of hospitalizations related to adverse drug reactions. The rate of fatal adverse drug reactions is difficult to determine, and it is probably underreported. As both adverse human effects and drug development costs increase, access to more reliable and affordable drug screening tools is increasingly critical."

Co-author Dr Aleksander Skardal, formerly of WFIRM and now at Ohio State University, said: "This increasing need to comprehensively screen new drugs for adverse effects is the driving force behind our research. In this context, we demonstrated our platform by screening a panel of FDA-recalled drugs for toxic effects.

"To model the integrated nature of the human body, we designed an integrated platform, or chip, supporting six tissue types under a common recirculating media. When combinations of organoids are combined into a single platform, more complex integrated responses can be seen, where the functionality of one organoid influenced the response of another."

To test their system, the researchers used it to screen six drugs that had been recalled due to adverse effects in humans: pergolide, rofecoxib, valdecoxib, bromfenac, tienilic acid and troglitazone. For many of these compounds, the 3D organoid system was able to demonstrate toxicity.

Professor Atala said: "These compounds were tested by the pharmaceutical industry and toxicity was not noted using standard 2D cell culture systems, rodent models, or during human Phase I, II and III clinical trials. However, after the drugs were released to market and administered to larger numbers of patients, toxicity was noted, leading the FDA to withdraw regulatory approval. In almost all these compounds, the 3D organoid system was able to readily demonstrate toxicity at a human-relevant dose."

As a control, they also tested the system with commonly-used drugs still on the market - aspirin, ibuprofen, ascorbic acid, loratadine, and quercetin. As well as not showing any toxicity, the organoids exposed to these non-toxic compounds remained viable at clinically-relevant doses.

Dr Skardal said: "Further study will be needed. But based on these results our system, and others like it, using 3D human-based tissue models with nuanced and complex response capabilities, has a great potential for influencing how in-vitro drug and toxicology screening and disease modelling will be performed in the near future."

IOP Publishing

Related Drugs Articles:

Wallflowers could lead to new drugs
Plant-derived chemicals called cardenolides - like digitoxin - have long been used to treat heart disease, and have shown potential as cancer therapies.
Bristol pioneers use of VR for designing new drugs
Researchers at the University of Bristol are pioneering the use of virtual reality (VR) as a tool to design the next generation of drug treatments.
Towards better anti-cancer drugs
The Bayreuth biochemist Dr. Claus-D. Kuhn and his research team have deciphered how the important human oncogene CDK8 is activated in cells of healthy individuals.
Separating drugs with MagLev
The composition of suspicious powders that may contain illicit drugs can be analyzed using a quick and simple method called magneto-Archimedes levitation (MagLev), according to a new study published in the journal Angewandte Chemie.
People are more likely to try drugs for the first time during the summer
American teenagers and adults are more likely to try illegal or recreational drugs for the first time in the summer, a new study shows.
Drugs used to enhance sexual experiences, especially in UK
Combining drugs with sex is common regardless of gender or sexual orientation, reveals new research by UCL and the Global Drug Survey into global trends of substance-linked sex.
Promising new drugs for old pathogen Mtb
UConn researchers are targeting a metabolic pathway, the dihydrofolate reductase pathway, crucial for amino acid synthesis to treat TB infections.
Can psychedelic drugs heal?
Many people think of psychedelics as relics from the hippie generation or something taken by ravers and music festival-goers, but they may one day be used to treat disorders ranging from social anxiety to depression, according to research presented at the annual convention of the American Psychological Association.
New uses for existing antiviral drugs
Broad-spectrum antiviral drugs work against a range of viral diseases, but developing them can be costly and time consuming.
New TB drugs possible with understanding of old antibiotic
Tuberculosis, and other life-threatening microbial diseases, could be more effectively tackled with future drugs, thanks to new research into an old antibiotic by the University of Warwick and the Francis Crick Institute.
More Drugs News and Drugs Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Warped Reality
False information on the internet makes it harder and harder to know what's true, and the consequences have been devastating. This hour, TED speakers explore ideas around technology and deception. Guests include law professor Danielle Citron, journalist Andrew Marantz, and computer scientist Joy Buolamwini.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at     You can read The Transition Integrity Project's report here.